AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$HIMS

Boughton Soleil sold $174K of HIMS

Boughton Soleil (Chief Legal Officer) sold 6,236 shares of Hims & Hers Health, Inc. (HIMS) at $27.86 ($0.17M total) on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boughton Soleil
Published Sep 17, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HIMS
Bearish
medium confidence
Mentioned
$HIMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to affect stock price materially.

02

Market read

Small insider sale with limited trading relevance.

03

What to watch

Insider may have tax or liquidity motives unrelated to company outlook.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑09‑16

Background

SEC Form 4 filing discloses insider transactions; HIMS is a telehealth provider.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

Chief Legal Officer sold 6,236 shares for $173,735 via a 10b5‑1 plan.

Expected impact

Minor downward pressure on HIMS price.

Evidence & confidence

Sale amount is under $200K and represents a small fraction of holdings; unlikely to move price significantly.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

Limited to US market participants tracking HIMS.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Officer
    Boughton Soleil

    Chief Legal Officer of Hims & Hers Health, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

SEP 22
$HIMSMed

Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks

The FTC, along with California and Utah regulators, filed a lawsuit against Hims & Hers on July 29, alleging privacy risks related to health data-sharing. The complaint was filed in the U.S. District Court for the Northern District of California. This legal action highlights concerns over consumer data protection in the health sector.

law360.com1 min
SEP 19
$HIMSMed

Telehealth companies keep exposing their customers' medical data. What should they do?

The FTC sued Hims & Hers for allegedly disclosing customer health data, signing users up for hard-to-cancel subscriptions, and bypassing real-time doctor consultations. Hims disputes the claims. Experts note federal laws often don't apply to telehealth companies, leading to data sharing with advertisers. Recent studies found many telehealth services lack proper physician consultations, especially for GLP-1 drugs. State laws offer some protections, but enforcement is limited. Privacy experts reco

newsday.com2 min
SEP 18
$HIMSHighAI 8/10

Class-action lawsuit filed against Hims & Hers following FTC complaint

A class-action lawsuit was filed against Hims & Hers (HIMS) on behalf of investors who acquired securities between 4 August 2025 and 29 July 2026, following an FTC complaint. The FTC alleges deceptive billing and unlawful sharing of health information. HIMS shares fell 14.73% on the news, closing at $25.00. The company denies the allegations.

dig.watch2 min
SEP 17
$HIMSHighAI 8/10

HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide

Hims & Hers Health (HIMS) stock fell 4% on Tuesday despite record subscriber growth and a Q2 revenue beat. Revenue rose 38% to $753M, but adjusted EBITDA dropped 27% to $60.3M. Morningstar noted margin concerns, while Deutsche Bank raised its price target to $26. The company raised its 2026 revenue forecast but lowered its EBITDA guidance.

stocktwits.com2 min
SEP 14
$HIMSMed

Why Hims & Hers Stock Is Suddenly Soaring

Hims & Hers Health (HIMS) stock surged following a $32 price target from JPMorgan, which projects $1.1B in GLP-1 weight-loss revenues by 2026. The rally was also driven by a new 3x leveraged long product on the LSE. The company has 3M subscribers and growing revenue, but faces debt and margin pressures.

tipranks.com2 min
SEP 11
$HIMSMed

JPMorgan cautious on Hims & Hers on GLP-1 transition risk

JPMorgan initiated coverage of Hims & Hers Health with a Neutral rating and a $32 price target for 2027. The firm acknowledges the company's growth but highlights risks in its transition to branded weight-loss drugs. Hims has 2.9 million subscribers and a partnership with Novo Nordisk for Wegovy shipments. JPMorgan projects 2026 GLP-1 revenue of $1.1 billion and long-term revenue growth to over $6.5 billion by 2030, but cautions on execution risks.

investing.com2 min